Abstract
The B-cell receptor signaling pathway is integral to the pathogenesis of most B-cell malignancies, including chronic lymphocytic leukemia (CLL). One potential target in that pathway is Bruton tyrosine kinase (BTK). Acalabrutinib (ACP-196), an irreversible BTK inhibitor, lacks much of the “off-target” binding of the first-in-class agent, ibrutinib. Investigators conducted a manufacturer-funded, uncontrolled trial of …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
